volrustomig + FOLFIRI + bevacizumab

This is a **combination therapy** comprising volrustomig, FOLFIRI, and bevacizumab: - **Volrustomig** is an investigational bispecific monoclonal antibody targeting PD-1 and TIGIT, designed to enhance anti-tumor immune responses and is under clinical development for various cancers. - **FOLFIRI** is a standard chemotherapy regimen composed of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. FOLFIRI works by disrupting DNA synthesis, preventing cancer cell division, and causing cell death. It is commonly used for metastatic colorectal cancer and other gastrointestinal cancers[1][3][5][7]. - **Bevacizumab** is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), reducing tumor blood vessel formation (anti-angiogenesis) and is approved for various advanced and metastatic malignancies including metastatic colorectal cancer[2][4][6].